TIDMONG
RNS Number : 6935E
Oxford Nutrascience Group PLC
12 April 2011
12 April 2011
Oxford Nutrascience Group plc
("Oxford Nutrascience" or "the Company")
Director Changes
Oxford Nutrascience, the specialty pharmaceutical company using
pharmaceutic and drug delivery science to develop advanced
medicines, announces the appointment of David Norwood as
Non-Executive Chairman of the Company with immediate effect.
Marcelo Bravo continues as Chief Technology Officer for the
Company.
Mr. Norwood (aged 42), former chief executive of the
stockbrokers Beeson Gregory and a former director of Evolution, is
the founder of the London Stock Exchange listed company, IP Group
plc, which specialises in the development of intellectual property
based businesses.
Mr. Norwood is one of the early shareholders in Oxford
Nutrascience and his appointment at the Company heralds Mr.
Norwood's long-standing commitment to building science based UK
businesses and his belief that the Company is now at a point of
inflection and poised for significant growth. David is currently
Chairman of Retroscreen Virology Limited, Europe's leading
specialist virology contract research organisation.
Oxford Nutrascience is developing a strong portfolio of
pharmaceutic and drug delivery technologies and is using these to
develop novel applications of generic or soon to be off patent
active pharmaceutical ingredients. Specifically, the company
specialises in formulating products that are easier or more
pleasant to take for geriatric or pediatric markets as well as
modified release formulations for various clinical benefits. The
Company's strategy is now primarily focused on the pharmaceutical
sector where a significant number of drugs are now generic and
where it is becoming increasingly difficult and expensive to bring
new drugs to market.
Nigel Theobald, Chief Executive of Oxford Nutrascience Group
plc, commented:
"It is not often that you get to work with someone of David's
calibre and it is a strong endorsement of the Company's prospects
that he has decided to join as Non-Executive Chairman.
"David's decision to come on board is testament to the exciting
opportunities ahead for the Company as we focus on the
pharmaceutical sector. The Board very much looks forward to the
Company benefitting from his significant experience."
For further information:
www.oxfordnutrascience.com
Oxford Nutrascience Group Plc
Nigel Theobald, Chief Executive +44 1865 854874
Mark Way, Investor and Media Relations +44 7786 116991
ZAI Corporate Finance (Nominated Adviser)
John Depasquale +44 20 7060 2220
Sarang Shah +44 20 7060 2220
Under Schedule 2, paragraph (g) of the AIM Rules, the following
information is disclosed:
Mr. David Robert Norwood has been a director / partner of the
following companies and partnerships:
Alexander Mining Plc
Amaethon Limited
Climatelabs Ltd
Energetix (Europe) Limited
EM Petroleum Plc
Green Chemicals Plc
Hatt III General Partner Limited
Ilika Technologies Limited
Invesco Perpetual Aim VCT Plc
IP Group Plc
IP2IPO Limited
IP2IPO Management Limited
IP2IPO Management II Limited
IP2IPO Services Limited
IP Ventures (Scotland) Limited
IP Venture Fund (GP) Limited
Kanyon Plc
Modern Biosciences Plc
Ora Capital Partners Plc
Oxeco Plc
Oxford Nanolabs Limited
Oxford Nutrascience Ltd
Solar Labs Plc
Southampton Asset Management Limited
Summit (Oxford) Limited
Summit Corporation Plc
Techtran Corporate Finance Limited
Techtran Group Limited
Techtran Investments Limited
Techtran Limited
Techtran Services Limited
Thermetica Limited
Top Technology Venture TTV IV G.P. Limited
Mr Norwood currently holds 87,514,300 Ordinary Shares in the
Company, equivalent to 17.5 per cent of its issued share capital.
Mr Norwood has confirmed that there is no additional information to
be disclosed in accordance with Schedule 2, paragraph (g) of the
AIM rules.
About Oxford Nutrascience Group Plc
-- Oxford Nutrascience is a speciality pharmaceutical company
that uses novel pharmaceutics and drug delivery science to develop
advanced medicines that extend the lifecycle of branded generics
and soon to be off patent API's.
-- Oxford Nutrascience has developed technology for the use of
prebiotic soluble fibres in medicine delivery systems that disperse
and solubilise medicines, improve taste and mouth feel, simplify
processing and eliminate additives.
-- Development work is currently focused on therapeutic
categories including analgesics, bone health, indigestion and
multivitamin and mineral supplements.
-- Oxford Nutrascience is establishing partnerships with a
number of leading academic centers for pharmaceutics and has a
growing number of technologies to apply to branded generics and
API's.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAMMGMDDMGGMZM
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxford Nutrascience (LSE:ONG)
Historical Stock Chart
From Dec 2023 to Dec 2024
